BioNTech is looking into taking legal steps against CureVac after the latter filed a patent lawsuit against it over its use of mRNA technology, BioNTech said on Wednesday, confirming a report by daily Welt.
“We are looking at all legal options,” said a BioNTech spokesperson.
CureVac is seeking “fair compensation” from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.
BioNTech has said in reaction that its work was original and it would defend it against all allegations of patent infringement.
By Reuters
Source: reuters.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.